Health TrialsbyHealthPanel

Remote Multichannel Monitoring of Patients With Chronic DIseAses Using Speech technoLogies Based On Artificial intelliGence

ConditionsHeart FailureDiabetes MellitusArterial HypertensionLymphoproliferative DiseaseTotal Knee Replacement
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorI.M. Sechenov First Moscow State Medical University

About this trial

DIALOG is a study to assess the efficacy and safety of remote patient monitoring using virtual operator voice technologies and a business intelligence (BI) system for timely detection, prevention of early complications, worsening of the condition, and other adverse events in patients who have been discharged from the hospital.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Disease diagnosed according to the latest Clinical practice guidelines

Stable condition at the time of discharge from the hospital

Written informed consent to participate in the study

Diagnosed dementia or severe cognitive impairment

Disqualifiers

Unwillingness of the patient to continue participating in the study

The development of conditions related to the criteria of non-inclusion

Trial design

Design model

Parallel

Treatments tested in this trial

  • Voice assistant

    Device

    Robotic remote monitoring of patients using unique algorithms developed for virtual operator speech technology and a BI system by voice commands on the "question-answer" principle. It allows us to automate data collection and obtain information about the patient's well-being and his vital signs (blood pressure, heart rate, weight) depending on disease. Follow-up and management of disease provided by specialists at participating institutions.

Treatment groups

500 Participants
are divided into 5 treatment groups
Group A: Heart FailureExperimental treatment 1 intervention
Group B: Diabetes mellitusExperimental treatment 1 intervention
Group C: Arterial hypertensionExperimental treatment 1 intervention
Group D: Lymphoproliferative diseasesExperimental treatment 1 intervention
Group E: Total knee replacementExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

cardiovascular mortality

mortality rate

Time frame
an average, 1 month after randomization
2

all-cause mortality

mortality rate

Time frame
an average, 1 months after randomization
3

complications, decompensations

rate of complications and exacerbations of the main disease

Time frame
an average, 1 month after randomization

Secondary outcomes

1

achievement target or maximally tolerated doses

achievement target or maximally tolerated doses for CHF, DM and AH

Time frame
an average, 1 month after randomization
2

satisfaction

satisfaction of patients and doctors with the robotic speech questionnaire

Time frame
an average, 1 month after randomization
3

changes in medical adherence

change in amount of taking drugs and doses

Time frame
an average, 1 month after randomization

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

I.M. Sechenov First Moscow State Medical University

Lead sponsor

PJSC VimpelCom

Collaborator

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: